MedTrace Logo

Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)

NCT01909362 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2014-02-26

No results posted yet for this study

Summary

Patients are being asked to participate in this study who have colorectal cancer that has come back after initial treatment. The investigators want to improve treatment in patients with this disease. In other types of cancers, it has been possible to improve treatment by studying the gene mutations (called biomarkers) in a patient's cancer and "matching" these to existing cancer therapies or study drugs which target that specific mutation. Colorectal cancers have not been routinely tested in this way.

In this study, investigators will determine whether mutational testing can be successfully done on colorectal cancers and how often mutations are detected for which there are existing drugs (or drugs in development). The results will be used to determine if treating physicians use this information in planning subsequent treatment.

Conditions

  • Colorectal Neoplasms
  • Advanced Metastatic Colorectal Cancer

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • US Oncology Research

    lead INDUSTRY

Principal Investigators

  • Ki Y. Chung, M.D. · US Oncology Research, McKesson Specialty Health

  • Donald A. Richards, M.D., Ph.D · US Oncology Research, McKesson Specialty Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01909362 on ClinicalTrials.gov